Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, Chapel Hill, North Carolina, USA.
Am J Gastroenterol. 2018 Jan;113(1):86-96. doi: 10.1038/ajg.2017.421. Epub 2017 Nov 14.
OBJECTIVES: The population prevalence of Rome IV-diagnosed functional gastrointestinal disorders (FGIDs) and their cumulative effect on health impairment is unknown. METHODS: An internet-based cross-sectional health survey was completed by 5,931 of 6,300 general population adults from three English-speaking countries (2100 each from USA, Canada, and UK). Quota-based sampling was used to generate demographically balanced and population representative samples with regards to age, sex, and education level. The survey enquired for demographics, medication, surgical history, somatization, quality of life (QOL), doctor-diagnosed organic GI disease, and criteria for the Rome IV FGIDs. Comparisons were made between those with Rome IV-diagnosed FGIDs against non-GI (healthy) and organic GI disease controls. RESULTS: The number of subjects having symptoms compatible with a FGID was 2,083 (35%) compared with 3,421 (57.7%) non-GI and 427 (7.2%) organic GI disease controls. The most frequently met diagnostic criteria for FGIDs was bowel disorders (n=1,665, 28.1%), followed by gastroduodenal (n=627, 10.6%), anorectal (n=440, 7.4%), esophageal (n=414, 7%), and gallbladder disorders (n=10, 0.2%). On average, the 2,083 individuals who met FGID criteria qualified for 1.5 FGID diagnoses, and 742 of them (36%) qualified for FGID diagnoses in more than one anatomic region. The presence of FGIDs in multiple regions was associated with increasing somatization, worse mental/physical QOL, more medical therapies, and a higher prevalence of abdominal surgeries; all P<0.001. Notably, individuals with FGIDs in multiple regions had greater somatization and worse QOL than organic GI disease controls. CONCLUSIONS: Roughly a third of the general adult population fulfils diagnostic criteria for a Rome IV FGID. In a third of this subset multiple GI regions are involved and this overlap is associated with increased health impairment.
目的:罗马 IV 诊断功能性胃肠疾病(FGIDs)的人群患病率及其对健康损害的累积影响尚不清楚。
方法:来自三个英语国家(美国、加拿大和英国各 2100 人)的 6300 名普通成年人群中,有 5931 人通过互联网完成了一项横断面健康调查。基于配额的抽样方法用于生成在年龄、性别和教育水平方面具有人口统计学平衡和代表性的样本。该调查询问了人口统计学、药物使用、手术史、躯体化、生活质量(QOL)、医生诊断的器质性胃肠道疾病以及罗马 IV FGIDs 的标准。将患有罗马 IV 诊断 FGIDs 的患者与非胃肠道(健康)和器质性胃肠道疾病对照组进行比较。
结果:与 3421 名非胃肠道和 427 名器质性胃肠道疾病对照组相比,有 2083 名(35%)患者出现符合 FGID 症状。最常符合 FGIDs 诊断标准的是肠道疾病(n=1665,28.1%),其次是胃十二指肠疾病(n=627,10.6%)、肛门直肠疾病(n=440,7.4%)、食管疾病(n=414,7.0%)和胆囊疾病(n=10,0.2%)。平均而言,符合 FGID 标准的 2083 名患者有 1.5 种 FGID 诊断,其中 742 名(36%)符合多个解剖部位的 FGID 诊断。多个部位存在 FGIDs 与躯体化增加、精神/身体 QOL 更差、更多医疗治疗以及更高的腹部手术患病率相关;所有 P<0.001。值得注意的是,多个部位存在 FGIDs 的个体比器质性胃肠道疾病对照组的躯体化和 QOL 更差。
结论:大约三分之一的普通成年人群符合罗马 IV FGID 的诊断标准。在这一部分人群中,有三分之一的患者多个胃肠道区域受累,这种重叠与健康损害增加有关。
Clin Gastroenterol Hepatol. 2018-5-29
Front Psychiatry. 2025-6-18
J Pediatr Gastroenterol Nutr. 2025-6-22
Nat Rev Gastroenterol Hepatol. 2025-4
Neurogastroenterol Motil. 2025-2
Neurogastroenterol Motil. 2017-7
United European Gastroenterol J. 2015-8-6
Gastroenterology. 2016-5
Gastroenterology. 2016-2-13
Gastroenterology. 2016-2-19
Aliment Pharmacol Ther. 2016-2-24
Neurogastroenterol Motil. 2016-2
Neurogastroenterol Motil. 2015-5
Aliment Pharmacol Ther. 2015-1-14